Kinderwunsch und Multiple Sklerose^[*]

Kernaussagen

Multiple Sklerose und Kinderwunsch schließen sich im Allgemeinen nicht aus. Negative Effekte auf die Erkrankung sind generell nicht zu erwarten. Der Vergleich mit gesunden Kontrollgruppen aus großen Datenbanken ergab auch einen weitgehend von der MS unabhängigen Schwangerschaftsverlauf aus gynäkologischer Sicht [97].

Wissenschaftler weltweit beschäftigen sich zunehmend mit diesem Themengebiet, sodass in den letzten beiden Jahren weitere Sicherheitsdaten zu Medikamenten (insbesondere Interferonen, zum kleinen Teil auch Natalizumab, Fingolimod, DMF und auch Teriflunomid) veröffentlicht wurden. Informationen finden sich auch in den Leitlinien des Kompetenznetzes Multiple Sklerose (KKNMS) (http://www.kompetenznetze-medizin.de/Netzwerke/NeurologischeErkrankungen/MultipleSklerose.aspx).

Um die schon bestehende Infrastruktur des Registers auch weiterhin zu nutzen, möchten wir mit diesem Artikel auf unser Schwangerschaftsregister hinweisen. Hierfür sind alle Schwangeren mit klinisch isoliertem Syndrom, MS oder auch NMO geeignet oder Frauen mit diesen Erkrankungen und kurzfristigem Kinderwunsch sowie Frauen mit MS und unerfülltem Kinderwunsch. Gerne können Sie sich selbst oder die Patientinnen am besten per E-Mail ([e-mail]) an uns wenden.

Weitere Informationen sind auch auf der Internetseite des Registers: www.ms-und-kinderwunsch.de zu finden.

^* Mod. nach Erstpublikation in Akt Neurol 2014; 41: 476–490

• Literatur

• 1 Orton SM, Herrera BM, Yee IM et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932-936
• 2 Cavalla P, Rovei V, Masera S et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci 2006; 27: 231-239
• 3 Jalkanen A, Alanen A, Airas L. Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler 2010; 16: 950-955
• 4 Thöne J, Kollar S, Nousome D et al. Serum anti-Müllerian hormone levels in reproductive-age women with relapsing remitting multiple sclerosis. Mult Scler 2015; 21: 41-47
• 5 Fachinformation. Betaferon® 250 Mikrogramm/ml. 2012. http://www.deutschesapothekenportal.de/fileadmin/bestellungen/fi_betaferon.pdf
• 6 Cocco E, Sardu C, Gallo P et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008; 14: 1225-1233
• 7 Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 2012; 72: 682-694
• 8 Laplaud DA, Leray E, Barriere P et al. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology 2006; 66: 1280-1281
• 9 Michel L, Foucher Y, Vukusic S et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 2012; 83: 796-802
• 10 Hellwig K, Beste C, Brune N et al. Increased MS relapse rate during assisted reproduction technique. J Neurol 2008; 255: 592-593
• 11 Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol 2013; 149: 219-224
• 12 Gold SM, Mohr DC, Huitinga I et al. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol 2005; 26: 644-652
• 13 Confavreux C, Hutchinson M, Hours MM et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285-291
• 14 Hellwig K, Brune N, Haghikia A et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand 2008; 118: 24-28
• 15 Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385-392
• 16 Schaefer C, Spielmann H, Vetter K, Weber-Schöndorfer C. Arzneimittel in Schwangerschaft und Stillzeit. 8. Aufl.. München: Elsevier, Urban & Fischer Verlag; 2012
• 17 Ruffatti A, Marson P, Pengo V et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 2007; 6: 196-202
• 18 Matok I, Levy A, Wiznitzer A et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012; 57: 699-705
• 19 Vukusic S, Hutchinson M, Hours M et al. Pregnancy In Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127: 1353-1360
• 20 Koch M, Uyttenboogaart M, Heersema D et al. Parity and secondary progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 676-678
• 21 DʼHooghe MB, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry 2010; 81: 38-41
• 22 Ramagopalan S, Yee I, Byrnes J et al. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2012; 83: 793-795
• 23 Airas L, Saraste M, Rinta S et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol 2008; 151: 235-243
• 24 Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol 2012; 8: 255-263
• 25 van der Kop ML, Pearce MS, Dahlgren L et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol 2011; 70: 41-50
• 26 Dahl J, Myhr KM, Daltveit AK et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005; 65: 1961-1963
• 27 Dahl J, Myhr KM, Daltveit AK et al. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol 2008; 255: 623-627
• 28 Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology 2009; 73: 1831-1836
• 29 Lu E, Zhao Y, Zhu F et al. British Columbia Multiple Sclerosis Clinic Neurologists. Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology 2013; 80: 447-452
• 30 Pastò L, Portaccio E, Ghezzi A et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol 2012; 12: 165
• 31 Borisow N, Döring A, Pfueller CF et al. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J 2012; 3: 9
• 32 Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 2013; 260: 1202-1214
• 33 Geissbühler YBH, Hernández-Diaz S et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry in Multiple Sclerosis. Lyon, France: ECTRIMS; 2012. (12 Oct): Abstract 751
• 34 Kieseier B, Benamor M, Truffinet P. Pregnancy Outcomes from the Teriflunomide Clinical Development Program Pactrims. 2013: P79.
• 35 Briggs GG, Freeman RK, Yaffe SJ. Classification of drugs for teratogenic risk: an anachronistic way of counseling: a reply to Merlob and Stahl. Birth Defects Res A Clin Mol Teratol 2003; 67: 207-208
• 36 Lu E, Wang BW, Guimond C et al. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology 2012; 79: 1130-1135
• 37 Amato MP, Portaccio E, Ghezzi A et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 2010; 75: 1794-1802
• 38 Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009; 15: 1037-1042
• 39 Sandberg-Wollheim M, Frank D, Goodwin TM et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65: 802-806
• 40 Sandberg-Wollheim M, Alteri E, Moraga MS et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011; 17: 423-430
• 41 Boskovic R, Wide R, Wolpin J et al. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005; 65: 807-811
• 42 Hellwig K, Haghikia A, Rockhoff M et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012; 5: 247-253
• 43 Fragoso YD, Adoni T, Alves-Leon SV et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013; 27: 955-961
• 44 Coyle PK, Johnson K, Pardo L et al. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003; 60: A60
• 45 Giannini M, Portaccio E, Ghezzi A et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol 2012; 12: 124
• 46 Ebrahimi N, Herbstritt S, Gold R et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015; 21: 198-205
• 47 Cristiano LBC, Bloomgren G. Preliminary evaluation of pregnancy outcomes from the Tysabri® (natalizumab) Pregnancy Exposure Registry. ECTRIMS 2011: P1005.
• 48 Fagiu J, Burman J. Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurol Scand 2014; 129: e27-e29
• 49 Haghikia A, Langer Gould A, Rellensmann G et al. Natalizumab use during third trimester of pregnancy. JAMA Neurol 2014;
• 50 Palmeira P, Quinello C, Silveira-Lessa AL et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646
• 51 Fachinformation. Gilenya®. Mai 2014.
• 52 Karlsson G, Francis G, Koren G et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014; 82: 674-680
• 53 Fachinformation. Tecfidera®. April 2014.
• 54 Gold R, Phillips JT, Havrdova E et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. 66th Annual Meeting of the American Academy of Neurology April 30, Philadelphia, Pennsylvania; 2014.
• 55 http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf
• 56 Fachinformation. AUBAGIO® 14 mg Filmtabletten. November 2013.
• 57 Chambers CD, Johnson DL, Robinson LK et al. Organization of Teratology Information Specialists Collaborative Research Group. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010; 62: 1494-1503
• 58 Cassina M, Johnson DL, Robinson LK et al. Organization of Teratology Information Specialists Collaborative Research Group. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012; 64: 2085-2094
• 59 Fachinfo. Lemtrada® 12 mg Konzentrat zur Herstellung einer Infusionslo¨sung. Dezember 2013.
• 60 Carp HJ, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun 2012; 38: 266-274
• 61 De Santis M, Straface G, Cavaliere AF et al. The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology 2007; 28: 696-697
• 62 Hellwig K, Schimrigk S, Chan A et al. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci 2011; 307: 164-165
• 63 Azuno Y, Kaku K, Fujita N. Mitoxantron and etoposid in breastmilk. Am J Hematol 1995; 48: 131-132
• 64 Giacalone PL, Benos P, Rousseau O. Chemotherapy for breast carcinoma during pregnancy. Cancer 1999; 86: 2266-2272
• 65 Reynoso EE, Huerta F. Acute leukemia and pregnancy – fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol 1994; 33: 703-716
• 66 Cocco E, Sardu C, Gallo P et al. FEMIMS Group. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008; 14: 1225-1233
• 67 Blumenfeld Z, Shapiro D, Shteinberg M et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000; 9: 401-405
• 68 Telez N, Gris J, Tintore M et al. Prevention of persistent ovarian failure after mitoxantrone in women with MS. Design of a treatment protocol with triptorelin. Multiple sclerosis 2006; 12 (Suppl. 01) P758
• 69 Ericson A, Källén BA. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001; 15: 371-375
• 70 Ratnayaka BD, Dhaliwal H, Watkin S. Neonatal convulsions after withdrawal of baclofen. Br Med J 2001; 323: 85
• 71 Moran LR, Almeida PG, Worden S et al. Intrauterine baclofen exposure: a multidisciplinary approach. Pediatrics 2004; 114: e267-269
• 72 Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27: 993-1002
• 73 Vajda FJ, Hitchcock AA, Graham J et al. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51: 805-810
• 74 Cunnington MC, Weil JG, Messenheimer JA et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011; 76: 1817-1823
• 75 Jentink J, Dolk H, Loane MA et al. EUROCAT Antiepileptic Study Working Group. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. Br Med J 2010; 341: c6581
• 76 Fujii H, Goel A, Bernard N et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 2013; 80: 1565-1570
• 77 Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723-1733
• 78 Nordeng H, van Gelder MM, Spigset O et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012; 32: 186-194
• 79 Colvin L, Slack-Smith L, Stanley FJ et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011; 91: 142-152
• 80 Merlob P, Birk E, Sirota L et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009; 85: 837-841
• 81 Hellwig KKM, Gold R, Langer-Gould A. Exclusive breastfeeding reduces the risk of postpartum relapses – a prospective study from the German MS and pregnancy registry: Experience from a nationwide database. Neurology 2011; 76: A272
• 82 Langer-Gould A, Huang SM, Gupta R et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009; 66: 958-963
• 83 Portaccio E, Ghezzi A, Hakiki B et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011; 77: 145-150
• 84 Airas L, Jalkanen A, Alanen A et al. Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology 2010; 75: 474-476
• 85 Pakpoor J, Disanto G, Lacey MV et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol 2012; 259: 2246-2248
• 86 Greenberger PA, Odeh YK, Frederiksen MC et al. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993; 53: 324-328
• 87 Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. J Hum Lact 2000; 16: 226-228
• 88 Hale TW, Siddiqui AA, Baker TE. Transfer of interferon β-1a into human breastmilk. Breastfeed Med 2012; 7: 123-125
• 89 de Seze J, Chapelotte M, Delalande S et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 2004; 10: 596-597
• 90 Achiron A, Rotstein Z, Noy S et al. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 1996; 243: 25-28
• 91 Achiron A, Kishner I, Dolev M et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004; 251: 1133-1137
• 92 Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 900-908
• 93 Portaccio E, Ghezzi A, Hakiki B et al. MS Study Group of the Italian Neurological Society. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry 2014; 85: 845-850
• 94 Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 2010; 257: 580-583
• 95 Lu E, Zhu F, Zhao Y et al. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler 2014; 20: 1260-1264
• 96 Pecori C, Giannini M, Portaccio E et al. MS Study Group of the Italian Neurological Society. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol 2014; 14: 114
• 97 Hanulíková P, Vlk R, Meluzínová E et al. Pregnancy and multiple sclerosis – outcomes analysis 2003–2011. Ceska Gynekol 2013; 78: 142-148
• 98 Hellwig K, Schimrigk S, Beste C et al. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol 2009; 61: 65-68
• 99 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdf
• 100 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000102/WC500029425.pdf
• 101 Fachinformation. Copaxone® 20 mg/ml. Mai 2014.
• 102 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000603/WC500148205.pdf
• 103 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf
• 104 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002601/WC500162070.pdf
• 105 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002514/WC500148684.pdf
• 106 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003718/WC500150522.pdf
• 107 Fachinformation. Ralenova® 2 mg/ml. Januar 2008.